Eli Lilly's oral obesity treatment efficacy falls short of expectations, says BMO's Evan Seigerman

Key Concepts:

• GLP-1 receptor agonists for weight loss (e.g., Wegovy, oral semaglutide/CMO)
• Efficacy and tolerability of weight loss drugs
• "Food effect" on oral medications
• Manufacturing costs of peptide-based drugs
• Pricing strategies and competition in the weight loss drug market
• Market expectations vs. actual clinical trial results
• Company messaging and investor perception

1. Market Reaction and Expectations:

• Eli Lilly's stock experienced a significant drop (down 14%) despite positive data, indicating that the market had "priced in perfection."
• Expectations for Lilly's drug efficacy were above 15%, fueled by statements from company executives.
• Novo Nordisk's stock surged, potentially due to a shift in market perception of competitive dynamics.

2. Oral Semaglutide (Oral Wegovy) vs. Injectable Wegovy:

• Novo Nordisk's oral semaglutide (CMO) showed 16.6% weight loss with good tolerability.
• Lilly's drug demonstrated 11% weight loss.
• Oral semaglutide may be better suited for weight maintenance after initial weight loss with injectables.
• The "food effect" is a critical consideration for oral semaglutide: it must be taken after fasting with a small amount of water, followed by a 30-minute wait before eating. Missing a dose due to eating immediately upon waking means skipping the dose for the day.

3. Competitive Landscape:

• The data suggests a more competitive market between Lilly and Novo Nordisk, with an opening for Novo.
• Differences exist in weight loss percentages, administration requirements (food effect), and manufacturing costs.
• Before the data release, the market perceived it was Lilly's market.

4. Manufacturing Costs and Pricing:

• Oral semaglutide requires a significantly higher dose of peptide (25mg) compared to injectable Wegovy (2.4mg), leading to higher manufacturing costs.
• Pricing headwinds are emerging in the weight loss drug space.
• CVS exclusive deal impacts both Novo Nordisk and Lilly's results.
• Novo Nordisk is offering larger rebates, indicating some pricing concessions, but not a "race to the bottom" yet.

5. Disconnect Between Company Messaging and Market Perception:

• A disconnect existed between Novo Nordisk's positive tone on their earnings call (highlighting 27 pounds average weight loss) and the market's more critical assessment.
• The analyst was surprised by the company's messaging, given the context of existing treatments and market expectations.
• Frustration arises when companies set high expectations (e.g., 25% with Categorysema, 15% with the drug in question) and then "fall flat," changing the narrative.
• David Ricks (Eli Lilly) was perceived as "tone deaf" to the stock drop following the data release.

6. Analyst Perspective and Advice:

• Companies should learn from their competitors' successes and failures.
• Covering both Lilly and Novo Nordisk provides a broader perspective.

7. Synthesis/Conclusion:

The weight loss drug market is highly competitive and sensitive to clinical trial results and company messaging. While both Lilly and Novo Nordisk have promising drugs, market expectations are high, and even slight differences in efficacy can significantly impact stock performance. The "food effect" of oral semaglutide and the higher manufacturing costs are key considerations. Pricing pressures are emerging, but a full-blown price war is not expected in the near term. Companies need to manage expectations carefully and learn from each other's experiences to succeed in this dynamic market.